Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma
- Authors:
- C. Karlisch
- K. Harati
- A. M. Chromik
- D. Bulut
- L. Klein-Hitpass
- O. Goertz
- T. Hirsch
- M. Lehnhardt
- W. Uhl
- A. Daigeler
-
Affiliations: Department of Gynecology and Obstetrics, Marienhospital Witten, Ruhr-University, D-58452 Witten, Germany, Department of Plastic Surgery, Burn Center, Hand Center, Sarcoma Reference Center, BG-University Hospital Bergmannsheil, D-44789 Bochum, Germany, Department of General and Visceral Surgery, St. Josef Hospital, Ruhr-University, D-44791 Bochum, Germany, Department of Medicine II, St. Josef Hospital, Ruhr-University, D-44791 Bochum, Germany, Institute for Cell Biology (Tumor Research), University of Duisburg-Essen, D-45122 Essen, Germany - Published online on: January 15, 2013 https://doi.org/10.3892/ijo.2013.1772
- Pages: 945-956
This article is mentioned in:
Abstract
Hoos A, Lewis JJ and Brennan MF: Soft tissue sarcoma: prognostic factors and multimodal treatment. Chirurg. 71:787–794. 2000.(In German). | |
Patrikidou A, Domont J, Cioffi A and Le Cesne A: Treating soft tissue sarcomas with adjuvant chemotherapy. Curr Treat Options Oncol. 12:21–31. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kaushal A and Citrin D: The role of radiation therapy in the management of sarcomas. Surg Clin North Am. 88:629–646. 2008. View Article : Google Scholar : PubMed/NCBI | |
O’Brien GC, Cahill RA, Bouchier-Hayes DJ and Redmond HP: Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Ir J Med Sci. 175:10–14. 2006.PubMed/NCBI | |
Solomon LR, Cheesbrough JS, Bhargava R, et al: Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis. Semin Dial. 25:233–238. 2012. View Article : Google Scholar | |
Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C and Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 112:1585–1591. 2008. View Article : Google Scholar | |
Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM and Brennan MF: Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 85:389–395. 1999. View Article : Google Scholar : PubMed/NCBI | |
Pezzi CM, Pollock RE, Evans HL, et al: Preoperative chemo-therapy for soft-tissue sarcomas of the extremities. Ann Surg. 211:476–481. 1990. View Article : Google Scholar : PubMed/NCBI | |
Donato Di Paola E and Nielsen OS: The EORTC soft tissue and bone sarcoma group. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 38(Suppl 4): S138–S141. 2002. | |
Nedea EA and DeLaney TF: Sarcoma and skin radiation oncology. Hematol Oncol Clin North Am. 20:401–429. 2006. View Article : Google Scholar : PubMed/NCBI | |
Brodowicz T, Schwameis E, Widder J, et al: Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma. 4:151–160. 2000. View Article : Google Scholar : PubMed/NCBI | |
Frustaci S, Gherlinzoni F, De Paoli A, et al: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 19:1238–1247. 2001.PubMed/NCBI | |
Bramwell V, Rouesse J, Steward W, et al: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 12:1137–1149. 1994. | |
Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 350:1647–1654. 1997. View Article : Google Scholar : PubMed/NCBI | |
Hirata T, Yonemori K, Ando M, et al: Efficacy of taxane regimens in patients with metastatic angiosarcoma. Eur J Dermatol. 21:539–545. 2011.PubMed/NCBI | |
Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY and Hohenberger P: Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol. 22:1266–1272. 2011.PubMed/NCBI | |
Mentzel T: Epithelioid sarcoma: morphologic variants and differential diagnosis. Pathologe. 31:135–141. 2010.PubMed/NCBI | |
Chromik AM, Daigeler A, Bulut D, et al: Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines. J Exp Clin Cancer Res. 29:212010. View Article : Google Scholar : PubMed/NCBI | |
Chromik AM, Daigeler A, Hilgert C, et al: Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J Invest Surg. 20:339–348. 2007. View Article : Google Scholar : PubMed/NCBI | |
Daigeler A, Chromik AM, Geisler A, et al: Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol. 32:1205–1220. 2008. View Article : Google Scholar : PubMed/NCBI | |
Daigeler A, Chromik AM, Haendschke K, et al: Synergistic effects of sonoporation and taurolidin/TRAIL on apoptosis in human fibrosarcoma. Ultrasound Med Biol. 36:1893–1906. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yagita H, Takeda K, Hayakawa Y, Smyth MJ and Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 95:777–783. 2004. View Article : Google Scholar : PubMed/NCBI | |
Bouralexis S, Findlay DM and Evdokiou A: Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis. 10:35–51. 2005. View Article : Google Scholar : PubMed/NCBI | |
Rowinsky EK: Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol. 23:9394–9407. 2005. View Article : Google Scholar | |
Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI | |
Ganten D, Ruckpaul K and Daniel P: Molekulare Grundlagen der Apoptose. Grundlagen der Molekularen Medizin. Springer Berlin; Heidelberg: pp. 159–203. 2008 | |
Newsom-Davis T, Prieske S and Walczak H: Is TRAIL the holy grail of cancer therapy? Apoptosis. 14:607–623. 2009. View Article : Google Scholar : PubMed/NCBI | |
LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10:66–75. 2003. View Article : Google Scholar : PubMed/NCBI | |
Beere HM: Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest. 115:2633–2639. 2005. View Article : Google Scholar : PubMed/NCBI | |
Jacobi CA, Menenakos C and Braumann C: Taurolidine - a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs. 16:917–921. 2005. View Article : Google Scholar : PubMed/NCBI | |
McCourt M, Wang JH, Sookhai S and Redmond HP: Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol. 7:685–691. 2000. View Article : Google Scholar : PubMed/NCBI | |
Petrovic L, Schlegel KA, Ries J, et al: In vitro effect of taurolidine on squamous cell carcinoma in the oral cavity. Mund Kiefer Gesichtschir. 7:102–107. 2003.(In German). | |
Gallagher KA, Liu ZJ, Xiao M, et al: Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest. 117:1249–1259. 2007. View Article : Google Scholar : PubMed/NCBI | |
Calabresi P, Goulette FA and Darnowski JW: Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res. 61:6816–6821. 2001.PubMed/NCBI | |
Braumann C, Henke W, Jacobi CA and Dubiel W: The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer. 112:225–230. 2004. View Article : Google Scholar : PubMed/NCBI | |
Neary PM, Hallihan P, Wang JH, Pfirrmann RW, Bouchier-Hayes DJ and Redmond HP: The evolving role of taurolidine in cancer therapy. Ann Surg Oncol. 17:1135–1143. 2010. View Article : Google Scholar : PubMed/NCBI | |
Darnowski JW, Goulette FA, Cousens LP, Chatterjee D and Calabresi P: Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol. 54:249–258. 2004. View Article : Google Scholar : PubMed/NCBI | |
Stendel R, Biefer HR, Dekany GM, et al: The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy. 5:194–210. 2009. View Article : Google Scholar : PubMed/NCBI | |
Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M and Mohler H: Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res. 23:2309–2314. 2003.PubMed/NCBI | |
Daigeler A, Brenzel C, Bulut D, et al: TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res. 27:822008. View Article : Google Scholar : PubMed/NCBI | |
Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J and Calabresi P: The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res. 22:1959–1964. 2002.PubMed/NCBI | |
Braumann C, Winkler G, Rogalla P, Menenakos C and Jacobi CA: Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine Report of a case. World J Surg Oncol. 4:342006. View Article : Google Scholar | |
Imhof L, Goldinger SM, Baumann K, et al: The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Res. Nov 3–2010.(Epub ahead of print). | |
Stendel R, Picht T, Schilling A, et al: Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res. 24:1143–1147. 2004.PubMed/NCBI | |
Backes C, Keller A, Kuentzer J, et al: GeneTrail - advanced gene set enrichment analysis. Nucleic Acids Res. 35:W186–W192. 2007. View Article : Google Scholar : PubMed/NCBI | |
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI | |
Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI | |
Tomek S, Koestler W, Horak P, et al: Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer. 39:1318–1329. 2003. View Article : Google Scholar : PubMed/NCBI | |
Clayer M, Bouralexis S, Evdokiou A, Hay S, Atkins GJ and Findlay DM: Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL. J Orthop Surg (Hong Kong). 9:19–22. 2001.PubMed/NCBI | |
Kondo K, Yamasaki S, Inoue N, et al: Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma. Surg Today. 36:966–974. 2006. View Article : Google Scholar | |
Walters DK, Muff R, Langsam B, Gruber P, Born W and Fuchs B: Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Invest New Drugs. 25:305–312. 2007. View Article : Google Scholar : PubMed/NCBI | |
Kluttermann K, Banning U, Kachel M, Krause C, Korholz D and Mauz-Korholz C: TRAIL-induced cytotoxicity in a melphalan-resistant rhabdomyosarcoma cell line via activation of caspase-2. Anticancer Res. 26:351–356. 2006.PubMed/NCBI | |
Komdeur R, Meijer C, Van Zweeden M, et al: Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Int J Oncol. 25:677–684. 2004.PubMed/NCBI | |
Heikaus S, Matuszek KS, Suschek CV, et al: Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L). J Cancer Res Clin Oncol. 134:689–695. 2008. View Article : Google Scholar : PubMed/NCBI | |
Gheorghescu B, Gherman I, Jovin GH, et al: Absorption studies in patients with parasitic infestation of the small intestine, before and after treatment. Med Interne. 14:31–38. 1976.PubMed/NCBI | |
Nedeau AE, Gallagher KA, Liu ZJ and Velazquez OC: Elevation of hemopexin-like fragment of matrix metalloproteinase-2 tissue levels inhibits ischemic wound healing and angiogenesis. J Vasc Surg. 54:1430–1438. 2011. View Article : Google Scholar : PubMed/NCBI | |
Nedea ME, Vasilescu F, Gheorghescu B, Pavelescu E and Runcan V: Determination with thin layer chromatography of the distribution of lipids in the feces and study of the incorporation of certain C 14 -labeled 1-fatty acids into the different lipid fractions. Fiziol Norm Patol. 19:67–73. 1973.(In Romanian). | |
Hollander MC, Poola-Kella S and Fornace AJ: Gadd34 functional domains involved in growth suppression and apoptosis. Oncogene. 22:3827–3832. 2003. View Article : Google Scholar : PubMed/NCBI | |
Hollander MC, Zhan Q, Bae I and Fornace AJ Jr: Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. J Biol Chem. 272:13731–13737. 1997. View Article : Google Scholar : PubMed/NCBI | |
Adler HT, Chinery R, Wu DY, et al: Leukemic HRX fusion proteins inhibit GADD34–induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins. Mol Cell Biol. 19:7050–7060. 1999.PubMed/NCBI | |
Grishin AV, Azhipa O, Semenov I and Corey SJ: Interaction between growth arrest-DNA damage protein 34 and Src kinase Lyn negatively regulates genotoxic apoptosis. Proc Natl Acad Sci USA. 98:10172–10177. 2001. View Article : Google Scholar : PubMed/NCBI | |
Chromik AM, Hahn SA, Daigeler A, et al: Gene expression analysis of cell death induction by taurolidine in different malignant cell lines. BMC Cancer. 10:5952010. View Article : Google Scholar : PubMed/NCBI | |
Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J and Jaattela M: Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev. 19:570–582. 2005. View Article : Google Scholar : PubMed/NCBI | |
Daugaard M, Rohde M and Jaattela M: The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett. 581:3702–3710. 2007. View Article : Google Scholar : PubMed/NCBI | |
Noguchi T, Takeno S, Shibata T, Uchida Y, Yokoyama S and Muller W: Expression of heat shock protein 70 in grossly resected esophageal squamous cell carcinoma. Ann Thorac Surg. 74:222–226. 2002. View Article : Google Scholar : PubMed/NCBI | |
Huang WJ, Xia LM, Zhu F, et al: Transcriptional upregulation of HSP70-2 by HIF-1 in cancer cells in response to hypoxia. Int J Cancer. 124:298–305. 2009. View Article : Google Scholar : PubMed/NCBI | |
Scieglinska D, Piglowski W, Mazurek A, et al: The HspA2 protein localizes in nucleoli and centrosomes of heat shocked cancer cells. J Cell Biochem. 104:2193–2206. 2008. View Article : Google Scholar : PubMed/NCBI | |
Garg M, Kanojia D, Seth A, et al: Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur J Cancer. 46:207–215. 2010. View Article : Google Scholar : PubMed/NCBI | |
Grivicich I, Regner A, Zanoni C, et al: Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines. Int J Colorectal Dis. 22:1201–1208. 2007. View Article : Google Scholar : PubMed/NCBI | |
Park SR, Lee KD, Kim UK, et al: Pseudomonas aeruginosa exotoxin A reduces chemoresistance of oral squamous carcinoma cell via inhibition of heat shock proteins 70 (HSP70). Yonsei Med J. 51:708–716. 2010. View Article : Google Scholar : PubMed/NCBI | |
Beere HM: ‘The stress of dying’: the role of heat shock proteins in the regulation of apoptosis. J Cell Sci. 117:2641–2651. 2004. | |
Valoti G, Nicoletti MI, Pellegrino A, et al: Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res. 4:1977–1983. 1998.PubMed/NCBI | |
Zhang L and Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI | |
Kuang AA, Diehl GE, Zhang J and Winoto A: FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem. 275:25065–25068. 2000. View Article : Google Scholar : PubMed/NCBI | |
Bodmer JL, Holler N, Reynard S, et al: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol. 2:241–243. 2000. View Article : Google Scholar : PubMed/NCBI | |
Petak I, Vernes R, Szucs KS, et al: A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells. Cell Death Differ. 10:729–739. 2003. View Article : Google Scholar : PubMed/NCBI | |
Piras V, Hayashi K, Tomita M and Selvarajoo K: Enhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rules. Sci Rep. 1:1442011. View Article : Google Scholar : PubMed/NCBI | |
Duckett CS: Apoptosis and NF-kappa B: the FADD connection. J Clin Invest. 109:579–580. 2002. View Article : Google Scholar : PubMed/NCBI | |
Park JM, Kim A, Oh JH and Chung AS: Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-kappaB activation. Carcinogenesis. 28:837–847. 2007. View Article : Google Scholar : PubMed/NCBI | |
Fiscella M, Zhang H, Fan S, et al: Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA. 94:6048–6053. 1997. View Article : Google Scholar : PubMed/NCBI | |
Lambros MB, Natrajan R, Geyer FC, et al: PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol. 23:1334–1345. 2010. View Article : Google Scholar : PubMed/NCBI | |
Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al: Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res. 15:2711–2722. 2009. View Article : Google Scholar : PubMed/NCBI | |
Tan DS, Lambros MB, Rayter S, et al: PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 15:2269–2280. 2009. View Article : Google Scholar : PubMed/NCBI | |
Xia Y, Ongusaha P, Lee SW and Liou Y-C: Loss of Wip1 sensitizes cells to stress- and DNA damage-induced apoptosis. J Biol Chem. 284:17428–17437. 2009. View Article : Google Scholar : PubMed/NCBI | |
Saito-Ohara F, Imoto I, Inoue J, et al: PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 63:1876–1883. 2003.PubMed/NCBI | |
Loukopoulos P, Shibata T, Katoh H, et al: Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci. 98:392–400. 2007. View Article : Google Scholar | |
Fuku T, Semba S, Yutori H and Yokozaki H: Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathol Int. 57:566–571. 2007. View Article : Google Scholar : PubMed/NCBI | |
Castellino RC, De Bortoli M, Lu X, et al: Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. 86:245–256. 2008. View Article : Google Scholar : PubMed/NCBI | |
Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M and Donehower LA: The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 27:123–135. 2008. View Article : Google Scholar : PubMed/NCBI | |
Rayter S, Elliott R, Travers J, et al: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene. 27:1036–1044. 2008. View Article : Google Scholar : PubMed/NCBI | |
Sorensen CS and Syljuasen RG: Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 40:477–486. 2012. View Article : Google Scholar : PubMed/NCBI | |
Mir SE, De Witt Hamer PC, Krawczyk PM, et al: In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 18:244–257. 2010. View Article : Google Scholar : PubMed/NCBI | |
Iorns E, Lord CJ, Grigoriadis A, et al: Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PloS One. 4:e51202009. View Article : Google Scholar : PubMed/NCBI | |
Posthuma DeBoer J, Wurdinger T, Graat HC, et al: WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer. 11:1562011.PubMed/NCBI | |
Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A and Florenes VA: High expression of wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PloS One. 7:e382542012. View Article : Google Scholar : PubMed/NCBI | |
Hirai H, Iwasawa Y, Okada M, et al: Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 8:2992–3000. 2009. View Article : Google Scholar | |
Rajeshkumar NV, De Oliveira E, Ottenhof N, et al: MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 17:2799–2806. 2011. View Article : Google Scholar : PubMed/NCBI | |
Bridges KA, Hirai H, Buser CA, et al: MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 17:5638–5648. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hirai H, Arai T, Okada M, et al: MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther. 9:514–522. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M and Altiok S: MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther. 11:174–182. 2012. View Article : Google Scholar : PubMed/NCBI | |
Saito YD, Jensen AR, Salgia R and Posadas EM: Fyn: a novel molecular target in cancer. Cancer. 116:1629–1637. 2010. View Article : Google Scholar : PubMed/NCBI | |
Chen Z-Y, Cai L, Bie P, et al: Roles of Fyn in pancreatic cancer metastasis. J Gastroenterol Hepatol. 25:293–301. 2010. View Article : Google Scholar : PubMed/NCBI | |
Koike K, Kogawa K, Takayama T, et al: Enhanced expression of type IV collagen-binding protein (p29) in Fyn-transfected murine fibrosarcoma cells. Jpn J Cancer Res. 93:1090–1099. 2002. View Article : Google Scholar : PubMed/NCBI |